Advancing Precision Oncology: Developing Translational Biomarkers for a Novel Mitochondrial-Targeted Therapy
- Therapeutic programs with novel targets and mechanisms of action present significant challenges when developing translational biomarkers to select patients and characterize treatment responses
- BTM-3566 modulates mitochondrial dynamics as a unique therapeutic strategy for treating tumors resistant to standard of care and those tumors with aggressive genomic profiles
- A summary of the scientific progression of this drug and the considerations for various biomarker strategies explored will be presented as well as current clinical study plans to develop a precision medicine product